No Data
[Brokerage Focus] China Securities Co., Ltd. maintains a "buy" rating on Remegen (09995), bullish on its commercial development and subsequent clinical advancement of innovative drugs.
China Securities Co., Ltd.'s research report pointed out that Remegen (09995) continued to see strong sales of its core products in the first half of the year, generating revenue of 0.742 billion yuan, achieving a good year-on-year growth. The company's core products, Taitaizipu and Videxitu, cover the areas of immunology and oncology, and the clinical development and commercialization of these two products are steadily progressing. In terms of the innovative pipeline, RC88 announced the latest research results on ovarian cancer at the ASCO conference, showing excellent product efficacy with promising future prospects. Overall, the bank is bullish on the company's commercial development and the subsequent clinical advancement of innovative drugs. The bank points out that the company has established and improved three major innovative drug R&D platforms, and has a strong competitive advantage in the field of innovative drugs.
Remegen (09995.HK) was reduced by Norges Bank by 0.543 million shares
According to the latest equity disclosure data from the Hong Kong Stock Exchange, on August 29, 2024, remegen (09995.HK) was reduced by Norges Bank on the exchange, with an average price of HK$11.9601 per share, reducing its holdings by 0.543 million shares, involving approximately HK$6.4943 million. After the shareholding, Norges Bank's latest shareholding is 9,068,432 shares, and the shareholding ratio has decreased from 5.07% to 4.78%.
RemeGen Co. Enhances Transparency on Incentive Plans
榮昌生物：有關2023年年報的補充公告
Hong Kong stocks fluctuate | Remegen (09995) falls more than 6% in the afternoon, with net losses in the first half of the year expanding by over 10%. Institutions have raised their forecast of net losses for the next three years.
Remegen (09995) fell more than 6% in the afternoon. As of the time of publication, it fell by 4.64% to 11.92 Hong Kong dollars, with a turnover of 34.7943 million Hong Kong dollars.
Hong Kong stocks fluctuate | Remegen (09995) fell more than 8% again, the first half of the year's losses expanded to 0.78 billion yuan, institutions lowered the forecast for peak sales of products.
remegen (09995) fell more than 8%, as of the time of the announcement, it fell 8.42% to HK$12.84, with a turnover of HK$36.8327 million.
No Data
